• Luyang Yang, Jinmeng Fan, Yunfeng Liu, Yi Ren, Zekun Liu, Hairui Fu, Hao Qi, and Jing Yang.
• Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
• Medicine (Baltimore). 2023 Jun 16; 102 (24): e33959e33959.

RationaleGitelman syndrome (GS) is an autosomal recessive tubulopathy caused by mutations of the SLC12A3 gene. It is characterized by hypokalemic metabolic alkalosis, hypomagnesemia and hypocalciuria. Hypokalemia, hypomagnesemia, and increased renin-angiotensin-aldosterone system (RAAS) activity can cause glucose metabolism dysfunction. The diagnosis of GS includes clinical diagnosis, genetic diagnosis and functional diagnosis. The gene diagnosis is the golden criterion while as functional diagnosis is of great value in differential diagnosis. The hydrochlorothiazide (HCT) test is helpful to distinguish GS from batter syndrome, but few cases have been reported to have HCT testing.Patient ConcernsA 51-year-old Chinese woman presented to emergency department because of intermittent fatigue for more than 10 years.DiagnosesLaboratory test results showed hypokalemia, hypomagnesemia, hypocalciuria and metabolic alkalosis. The HCT test showed no response. Using next-generation and Sanger sequencing, we identified 2 heterozygous missense variants (c.533C > T:p.S178L and c.2582G > A:p.R861H) in the SLC12A3 gene. In addition, the patient was diagnosed with type 2 diabetes mellitus 7 years ago. Based on these findings, the patient was diagnosed with GS with type 2 diabetic mellitus (T2DM).InterventionsShe was given potassium and magnesium supplements, and dapagliflozin was used to control her blood glucose.OutcomesAfter treatments, her fatigue symptoms were reduced, blood potassium and magnesium levels were increased, and blood glucose levels were well controlled.LessonsWhen GS is considered in patients with unexplained hypokalemia, the HCT test can be used for differential diagnosis, and genetic testing can be continued to confirm the diagnosis when conditions are available. GS patients often have abnormal glucose metabolism, which is mainly caused by hypokalemia, hypomagnesemia, and secondary activation of RAAS. When a patient is diagnosed with GS and type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) can be used to control the blood glucose level and assist in raising blood magnesium.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…